Clinical trial NCT05974397: Nationwide Trends in Incidence, Healthcare Utilization, and Mortality in Hospitalized Acute Myocardial Infarction Patients in Taiwan
Official title: Nationwide Trends in Incidence, Healthcare Utilization, and Mortality in Hospitalized Acute Myocardial Infarction Patients in Taiwan
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Myocardial Infarction
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2023-08-03
Enrollment: 124018
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This was a retrospective, noninterventional cohort study.

Brief summary: This was a retrospective study using the Taiwan's National Health Insurance Research Database (NHIRD). The study employed two study designs for different purposes as follows:

* A cross-sectional analysis was conducted to explore the annual incidence trends.
* A longitudinal cohort study was conducted to assess baseline characteristics, treatment patterns, long-term healthcare utilization, and cause-specific mortality among incident AMI patients.

In each part, the study was conducted for AMI, and separately for ST-segment elevation and non-ST- segment elevation myocardial infarction (STEMI and NSTEMI)


Eligibility criteria: Inclusion Criteria:

Cross-sectional analysis:

* Patients aged 20 years and older.
* Patients who had been admitted for AMI, defined as primary or first secondary diagnosis of AMI between 2014 and 2020.
* The diagnosis of AMI/ STEMI/ NSTEMI was identified by the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes and 10th revision (ICD-10-CM) codes.
* Incident cases of AMI hospitalization were defined as no history of AMI-related hospitalization or outpatient visit within 1 year before admission.

Longitudinal analysis:

Patients aged 20 years and older.

* Patients who had been admitted for AMI, defined as primary or first secondary diagnosis of AMI between 2014 and 2017.
* The diagnosis of AMI/ STEMI/ NSTEMI was identified by ICD-9-CM codes and ICD-10-CM codes. (The ICD-9-CM code and ICD-10-CM codes were the same as above)
* Incident cases of AMI hospitalization were defined as no history of AMI-related hospitalization or outpatient visit within 1 year before admission.
* The cohort entry date was defined as the admission date of incident AMI hospitalization, and the index date was defined as the discharge date of incident hospitalization.

Exclusion Criteria:

None specified

Primary outcomes:
measure: Mean age of patients
timeFrame: 12 months
measure: Number of male patients
timeFrame: 12 months
measure: Year of patient entry into cohort
timeFrame: 12 months
measure: Number of patients with AMI in Taiwan
timeFrame: 12 months
measure: Number of patients with STEMI in Taiwan
timeFrame: 12 months
measure: Number of patients with NSTEMI in Taiwan
timeFrame: 12 months
measure: Number of AMI patients with comorbidities
timeFrame: Up to 3 years
measure: Number of patients with treatment for AMI
timeFrame: Up to 3 years
measure: Number of STEMI patients with comorbidities
timeFrame: Up to 3 years
measure: Number of patients with treatment for STEMI
timeFrame: Up to 3 years
measure: Number of NSTEMI patients with comorbidities
timeFrame: Up to 3 years
measure: Number of patients with treatment for NSTEMI
timeFrame: Up to 3 years
measure: Number of mortalities among AMI patients
timeFrame: Up to 3 years
measure: Number of mortalities among STEMI patients
timeFrame: Up to 3 years
measure: Number of mortalities among NSTEMI patients
timeFrame: Up to 3 years
measure: Number of AMI patients with outpatient visits
timeFrame: Up to 3 years
measure: Number of AMI patients with emergency room visits
timeFrame: Up to 3 years
measure: Number of AMI patients with hospitalizations
timeFrame: Up to 3 years
measure: Length of hospital stay for AMI patients
timeFrame: Up to 3 years
measure: Direct medical costs for AMI patients
timeFrame: Up to 3 years
measure: Number of STEMI patients with outpatient visits
timeFrame: Up to 3 years
measure: Number of STEMI patients with emergency room visits
timeFrame: Up to 3 years
measure: Number of STEMI patients with hospitalizations
timeFrame: Up to 3 years
measure: Length of hospital stay for STEMI patients
timeFrame: Up to 3 years
measure: Direct medical costs for STEMI patients
timeFrame: Up to 3 years
measure: Number of NSTEMI patients with outpatient visits
timeFrame: Up to 3 years
measure: Number of NSTEMI patients with emergency room visits
timeFrame: Up to 3 years
measure: Number of NSTEMI patients with hospitalizations
timeFrame: Up to 3 years
measure: Length of hospital stay for NSTEMI patients
timeFrame: Up to 3 years
measure: Direct medical costs for NSTEMI patients
timeFrame: Up to 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Novartis
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References: